ArticleFrontiers in pharmacology2022

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.

Yan Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.